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Abstract
Angiogenesis, a natural phenomenon of developing new blood vessels, is an integral 
part of normal developmental processes as well as numerous pathological states in 
humans. The angiogenic assays are reliable predictors of certain pathologies in particu-
lar tumor growth, metastasis, inflammation, wound healing, tissue regeneration, isch-
emia, cardiovascular, and ocular diseases. The angiogenic inducer and inhibitor studies 
rely on both in vivo and in vitro angiogenesis methods, and various animal models 
are also standardized to assess qualitative and quantitative angiogenesis. Analogously, 
the discovery and development of anti-angiogenic agents are also based on the choice 
of suitable angiogenic assays and potential drug targeted sites within the angiogenic 
process. Similarly, the selection of cell types and compatible experimental conditions 
resembling the angiogenic disease being studied are also potential challenging tasks 
in recent angiogenesis studies. The imaging analysis systems for data acquisition from 
in vivo, in vitro, and in ova angiogenesis assay to preclinic, and clinical research also 
requires novel but easy-to-use tools and well-established protocols. The proposition of 
this pragmatic book chapter overviews the recent advances in angiogenesis assessment 
methods and discusses their applications in numerous disease pathogenesis.
Keywords: angiogenesis techniques, in vitro angiogenesis, angiogenic mouse models, 
quantitative angiogenesis, transgenic animal models, angiogenesis in clinical practice, 
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1. Introduction
The growth of new microvessels from the parent ones is an integral part of new tissue growth 
in growing organisms. It plays an essential part in human health while playing key roles 
in wound healing and tissue development [1]. Similarly, the phenomenon is regularly trig-
gered in certain pathological conditions including rheumatoid arthritis, endometriosis, 
diabetic retinopathy, macular degeneration, tumor growth, and inflammatory conditions 
in response to certain antigens and toxins [2]. However, almost every normal tissues lack 
this phenomenon in adulthood, except cyclical events in the female reproductive organs [3]. 
Physiological angiogenesis in tissues contains a natural balance between endogenous pro- 
and anti- angiogenic factors [3]. When this balance gets disturbed and shifts more toward 
the pro-angiogenic side in certain pathological states (inflammation, ischemia, hypoxia, and 
cancer), microvascular endothelial cells (ECs) initiate a cascade of angiogenic reactions which 
may be retracted or progressive and turn microvessels to an angiogenic phenotype [4]. A 
considerable diversity exists among microvascular endothelial cells in different tissues and 
organs, and species heterogeneity cannot be ignored in this scenario [4].
Where angiogenesis is useful for tissue growth and development, excessive vessel growth is 
really problematic and a hallmark to propagate many diseases while contributing to turn-
ing tumor cells into cancer, tumor metastasis, psoriasis, arthritis, diabetic retinopathy, and 
predominantly metabolic disease such as obesity, atherosclerosis, and certain infectious dis-
eases [5]. Conversely, insufficient angiogenesis or neovascularization may cause ischemic tis-
sue states in heart, brain, and peripheral muscles which may lead to high blood pressure, 
preeclampsia, neurodegeneration, and osteoporosis [5]. In such pathological states, pro-
angiogenic therapies which promote compensatory angiogenesis show promise to treat such 
pathologies [6]. In parallel to that, angiogenic inhibitors found highly effective in clinical tri-
als as successful strategic treatment approaches with or without conventional chemotherapy 
for the treatment of solid tumors and metastasis [7]. The potential beneficiary of such novel 
treatment strategies are patients with aberrant ocular angiogenesis and cancer patients, where 
defective sight and cancer progression are entirely angiogenesis-dependent [7]. Such treat-
ment paradigms are also heralding a new era of the treatment for other commonly occurring 
angiogenesis-related diseases.
The formation of new vessels involves many different cell types, and an intricate interplay of 
various endogenous vascular growth factors, receptors, extracellular matrix (ECM) proteins and 
the humoral factors [8]. To design and develop potentially effective pro- and anti-angiogenic 
treatments and to understand molecular mechanisms involved in angiogenesis and neovas-
cularization, numerous in vivo and in vitro assays and animal models of angiogenesis have 
been developed [9]. Similarly, preclinical angiogenesis assays have also used for drug screen-
ing, molecular structure activities, and dosage effects of certain approved anti-angiogenic 
compounds although such assays are not equivalent and relevant to human disease regarding 
efficacy [10]. The prime objective of this book chapter is to overview current major and newly 
introduced angiogenic assays with regard to major advantages and limitations from biological, 
technical, ethical, and economic perspectives. The major assays which we discuss here include 
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corneal micropocket assay, CAM (chick chorioallantoic membrane) assay, rodent mesentery, 
Matrigel plug assays, whole-animal assays (zebrafish), and animal models of angiogenesis in 
the context of cardiovascular, ocular, and adipose tissue diseases. A precise note on genetically 
engineered animal models for vascular endogenous genes and their spatial, temporal, and con-
ditional expression is also included [9]. It is beyond the scope of this chapter to cover every 
angiogenesis assays in details, so we briefly overview quantitative techniques and/or methods 
to assess/evaluate neovascularization in tissues. We also briefly discuss molecular mechanisms 
and cell signaling pathways involved in angiogenesis and potential anti-angiogenic therapies, 
their clinical impact, limitations, and future prospects.
2. Prerequisite for good angiogenesis assays
Before to choose an ideal assay for angiogenesis studies, the investigators and researchers 
must know the assay kinetics in terms of operating procedures, handling the environment, 
ethical justification, and assay economy [8]. In vivo angiogenic studies are more informative 
than in vitro due to complex cellular and molecular activities of angiogenic reactions while 
providing biology of the assay and showing experimental design are relevant [9]. Similarly, in 
trauma-based assays (either physical or chemical), where cell damage triggers inflammatory 
reactions which mimic the release of several pro-angiogenic cytokines, the sensitivity and 
specificity of the assay are reduced [10]. For such assays, specific precautions must be taken to 
avoid any inflammatory reaction or to minimize the traumatic tissue state. In parallel to that, 
the test substance/compound should be designed as being angiogenic in a noninflammatory 
state. A near to physiological dose of the test compound should be administered for inducing 
an angiogenic response while to modulate angiogenic assay conditions and dosage response, 
a dose range of the clinical use must be chosen [10].
Vehicles carrying the test compound in many assays may also affect the pharmacokinetics 
of the tested drug and alter the dose-response curves among different experimental animals 
within one group. For such circumstances, the best solution is to compare test animals/sam-
ples with vehicle-exposed counterparts [9]. However, for data interpretation, one must be 
fully acquainted with the fact that how the vehicle-administered tested animals differ from 
the untreated controls [10]. Spatial and temporal distributions of the tested compounds are 
also necessary and vital because failure to do so may produce or hinder to generate reliable 
and rigorous dose-response curves [10]. As in different pathological states newly formed, 
vessels are delicate in quality and poorly functional, the selection of angiogenic assessment 
methods (either qualitative or quantitative) also matters to evaluate the morphology and 
physiology of the neovascularization in diseased tissues [9]. For in vivo angiogenesis assays, 
histological microscopy provides the detailed information precisely. Mammalian systems 
adopted for in vivo angiogenesis assays and mouse models for certain cardiovascular, ocu-
lar, and cerebral diseases are comparatively more close to relating human pathophysiol-
ogy than the embryonic CAM assay, embryonic zebrafish (Xenopus laevis), and invertebrate 
(Hirudo medicinalis) angiogenic assays [9, 10].
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3. Key components of an ideal angiogenesis assay
It would be interesting to describe that despite the much progress in the field of angiogenesis 
research, there is no single angiogenic model available which may fully elucidate the entire pro-
cess and molecular mechanisms of the angiogenic and neovascularization process. Some exog-
enous and endogenous factors hinder the efforts to develop such an ideal system. Due to cell 
diversity among different tissues where angiogenesis takes place and intricate interplay among 
different cell signaling pathways of angiogenic reactions, it is an uphill task to develop and vali-
date a unique assay that is optimal for all situations. However, different modalities and ingenious 
ways with the passage of time in a particular assay facilitate and provide optimisms for better 
measurements of angiogenesis than the past. In this context, Vallee et al. [11] conclude that “The 
design and verification of [new] specific, reliable, repeatable, and precise methodology to measure 
angiogenesis are considered an imperative of high priority in the field of angiogenesis research.” 
Similarly, Auerbach et al. [10] state “Perhaps the most consistent limitation in all these studies and 
approaches has been the availability of simple, reliable, reproducible, quantitative assays of the 
angiogenic response.” Moreover, it is challenging although not impossible in several angiogenic 
assays that the quantification of newly formed vessels regarding numbers and lengths. Similarly, 
the spatial and temporal distribution of tested compound is also necessary to get strong dose-
response curves. Performing an assay in a blinded manner may helpful in this prospect and also 
to alleviate the influence of any preconceived notions. Analogously, the technical skills to perform 
any angiogenesis assay are of utmost importance to ensure maximum success.
Despite all these qualms as described above, an ideal angiogenesis assay for quantification of 
newly formed vessels must feature the following characteristics; first [12], “the release rate [R] 
and the spatial and temporal concentration distribution [C] of tested compounds should be 
known to evaluate dose-response curves; second, if tumor cells are used as a source of angio-
genic factors, oncogene expression and production of growth factors (either stimulants or inhib-
itors) must be genetically well defined before the assay proceeding; third, the assay must be 
designed in a way ensure to provide quantitative measuring parameters of the newly formed 
vessels (e.g., vascular length [L], surface area [A], volume [V], number of vessels in the network 
[N], fractal dimensions of the network [Df], and extent of basement membrane [BM]); fourth, 
the assay should be designed in a way to weigh quantitative measure of morphological charac-
teristics of new vessels (e.g., endothelial cell migration [MR], proliferation rate [PR], canaliza-
tion rate [CR], blood flow rate [F], and vascular permeability [P]); fifth, a clear demarcation must 
exist between new and parent vessels; sixth, tissue trauma must be minimized to prevent the 
formation of new vessels; seventh, in vitro assessment should be verified by in vivo procedures; 
eighth, angiogenesis assay for long term and with noninvasive monitoring should be preferred; 
last, the selected assay should be economical, ethically justifiable, robust, and reliable.” [12].
4. Process of angiogenesis
Endothelial cell activation, proliferation, and directed migration to form new microvasculature 
(capillaries) from the parent ones should be a complex process involving many molecular and 
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cell signaling pathway events [2]. Some key regulators to switch on or off gene expression are 
also participating and influence by positive and negative feedbacks of cellular processes. The 
normal physiological angiogenesis initiates by sprouting of capillaries under the effect of vascu-
lar endothelial growth factors (VEGFs) from parent vessels [13]. It continuous during embryonic 
development and transiently during female reproductive cycle but almost stops in adult tissues 
except for some wound healing states [13]. Pathologic angiogenesis remains persistent with the 
continuous proliferation of ECs in different tissue pathologies and particularly in cancer [3]. 
Many tumor cells are capable of attracting adjacent blood vasculature from nearby tissues [2]. It 
was evident by the fact that for solid tumors to grow a certain size, neovascularization is neces-
sary otherwise such tumors rarely metastasize as found in thin melanomas which reside on the 
avascular basement membrane [2, 13]. Also, for tumor growth, the nutrient supply, oxygen, and 
waste removal are also essential. The new vasculature fulfills this task while providing immune 
cells, macrophages, and humoral factors to the vicinity of the tumor cells [2].
The parent vessel wall comprises endothelial cell lining, basement membrane, and pericytic 
cells. Pro-angiogenic growth factors (VEGF, TGF-α, TNF-α) from tumor cells bind to the recep-
tors of ECs and initiate a cascade of cell signaling pathways and angiogenic reactions [2]. 
Activation and resolution of ECs are two key steps of the angiogenic cascade reactions. When 
ECs activate and stimulate to grow, the cells secrete proteases, heparanase, and other digestive 
enzymes that degrade the extracellular matrix (ECM) [13]. ECM degradation allows the secre-
tion of many pro-angiogenic factors from the endothelial cell matrix, and the junctions between 
ECs become leaky; new microvessel sprouts grow in the direct toward the stimulus [2] (Figure 
1). For further ECs to grow, proliferate, and migrate, hematopoietic-endothelial progenitor cells 
(HEPC) also play an essential role [13]. In resolution phase, the new microvasculature tends 
to mature with the help of pericytic cell adhesion, reconstitution of basement membrane, and 
Figure 1. Process of angiogenesis from parent vessels: Angiogenesis sprouting initiates when vascular endothelial 
growth factors (e.g., VEGF-A) bind to VEGFR-2 receptors located on endothelial cells (ECs). ECs release matrix 
metalloproteinase (MMP) which degrades extracellular matrix (ECM) from which endothelial tip cells migrate. 
Vascular endothelial growth factors also regulate Notch cell signaling to inhibit proliferation of endothelial stalk cells. 
Platelet-derived growth factor (PDGF) released from ECs recruits smooth muscle cells (e.g., pericyte) to stabilize the 
neovasculature. TGF-α = transforming growth factor, TNF-α = tumor necrosis factor.
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formation of cell junctions [14]. Interestingly, the resolution phase in tumor surrounding capil-
lary network remains incomplete which results in irregular and tortuous microvasculature with 
partial ECs, increased cell permeability, and fragmentary basement membrane [15]. Tumor 
vasculature is disorganized with poor microcirculation, and vessel diameter changes without 
any differentiation into arterioles, capillaries, and venules [13]. Similarly, tumor vasculature is 
sprouting type, so assays which quantify sprouting angiogenesis are very useful to study the 
kinetics of tumor angiogenesis [15].
In the following section, we present the major and currently used preclinical angiogenesis 
assays in approximate chronological order of their first publication like chick chorioallantoic 
membrane (CAM), Matrigel plug, and corneal micropocket assays, while the others described 
in brief. [10]. CAM, Matrigel plug, and zebrafish assays are very useful for new angiogenic 
inhibitors screening. For a particular research focus, we provide advantages and disadvantages 
between different assays in a tabular form feasible for the readers (Table 1).
Assay name Advantages Disadvantages
In vivo angiogenesis assays
Corneal micropocket assay (a) Easy-to-identify newly formed 
vessels
(a) Atypical assay due to avascular tissue 
nature
(b) Easy to perform in animals (e.g., 
mice, rat, and rabbit)
(b) Induction of nonspecific 
inflammation to test substance
(c) Qualitatively permits noninvasive 
and long-term monitoring
(c) Inaccessible to endogenous blood-
borne angiogenic factors
(d) Immunologically, cross reaction 
is minimized
(d) Ethical problems as using a major 
sensory organ for angiogenic assay
(e) New vessel formation by 
sprouting
(e) Oxygen exposure may affect 
angiogenesis
(f) Not a suitable site for tumor growth
(g) Tested compounds are few
Chick chorioallantoic membrane 
assay
(a) Simple to perform and low in 
cost
(a) Inflammation-mediated angiogenic 
reactions
(b) Suitable to study pro- and anti-
angiogenic compounds
(b) Very sensitive to change in O
2
 tension
(c) Tumor angiogenesis may assess (c) Not suitable for metabolically 
activated compounds
(d) Embryonic nonmammalian 
procedure
(e) Newly formed vessels are difficult to 
identify
Rodent mesentery assays (a) Natively sparsely vascularized (a) Less significant for quantitative 
angiogenesis in mice than rats
(b) Lacks physiological angiogenesis (b) Real-time observation is limited
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Assay name Advantages Disadvantages
(c) Angiogenesis induction with little 
or no trauma
(c) Technically require skills and time 
consuming
(d) Suitable for quantitative 
measurement of microvessel variables 
(e.g., spatial extension, density, vessel 
number and length)
(e) Suitable to study tumor 
angiogenesis
(f) Sprouting type of angiogenesis
Sponge/matrix implant assay (a) Simple and inexpensive to proceed (a) Nonspecific inflammatory host 
responses
(b) Replicate in hypoxic tumor 
microenvironment so convenient for 
tumor angiogenesis studies
(b) Implant/sponge composition may 
vary
(c) Reproducible and continuous 
assessment of angiogenesis
(c) s.c is not a reliable route for tumor 
growth
(d) Variable drug retention within 
implant
Disk angiogenesis assay (a) Inexpensive and easy to perform (a) Continuous or kinetic observation is 
limited
(b) Quantitative assessment of 
angiogenesis
(b) Encapsulated by granulation tissue
(c) Wound healing may access
(d) Multiple disks can be used at one 
time
Matrigel plug assay (a) Rapid screening of pro- and anti-
angiogenic compounds
(a) Matrigel chemical composition is not 
defined
(b) An experimental model for tissue 
regeneration
(b) Three-dimensional plugs are difficult 
to generate
(c) Simple to proceed and rapid 
screening in chambers
(c) Avascular test tissue
Whole-animal models for angiogenic assays
Xenopus laevis (Zebrafish) (a) Embryonic and organogenic 
angiogenesis is assessed
(a) Expensive in breeding condition
(b) Useful animal model for functional 
genomic analysis
(b) Non-mammalian and embryonic in 
nature
(c) Simple to proceed and relatively 
fast
(d) Easy animal maintenance and 
significant number of tested animals 
per statistical analysis
(e) Single-drug dosing and small 
quantities of drugs are required
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Assay name Advantages Disadvantages
Mouse models of angiogenesis
Adipose angiogenesis models
1. ob/ob mice (a) Deficient in leptin (a) Expensive in terms of handling and 
treatment
(b) Suitable to study angiogenesis in 
adipose tissue expansion
(b) Time consuming to assess 
angiogenesis
(c) Helpful to test compounds related 
to metabolic disorders and obesity
2. Db/db mice (a) Excellent for role of angiogenesis in 
insulin resistance and obesity-related 
diabetes
(a) Difficult to handle and time 
consuming
Cardiovascular angiogenesis mouse models
1. Hindlimb ischemic model (a) Suitable to study arteries growth in 
tissue hypoxia
(a) Hind limb surgery is complicated
(b) Can be performed in mice or rat (b) Skilled and experienced person is 
required
(c) Suitable to use for therapeutic 
agents which augment perfusion to 
ischemic limb
(c) Degree of tissue hypoxia may vary 
within experimental animals group
(d) Residual blood flow may slightly 
differ in limb after surgery
2. Heart ischemic model (a) Suitable for pathological and drug 
evaluation studies
(a) Inflammatory response–mediated 
angiogenesis
(b) Efficient neovascularization
Wound healing assays (a) Suitable for vascular maturation/
remodelling studies
(a) Inflammatory responsemediated 
angiogenesis
(b) Surgery is very simple (b) limited to skin regeneration
(c) Pro- or anti-angiogenic compounds 
can be tested for vessel morphology or 
regenerative angiogenesis
(c) Regeneration through new tissue 
formation instead repairing and 
replacing damaged tissue
(d) Very easy and robust assay
Transgenic animal models
1. Transgenic choroidal 
neovascularization model
(a) Controlling transgene conditional 
expression and evaluation of spatial 
and temporal vascular gene 
expression
(a) Ethically questionable
2. Transgenic zebrafish model (b) Knock-down vascular endogenous 
gene expression
(b) Time consuming
(c) Differential gene expression may 
observed within same animal
Table 1. The advantages and disadvantages of major in vivo, in vitro and animal models angiogenesis assays.
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5. In vivo angiogenesis models
5.1. The corneal micropocket assay
The firm foundation of systematic angiogenesis research was initiated by Folkman and asso-
ciates who introduced first time the corneal micropocket assay and chick chorioallantoic 
membrane (CAM assay) in 1974 [16, 17]. The corneal micropocket assay allows the growth 
of newly formed blood vessels in vivo, and the techniques were first time applied in rabbits 
and after that in mice and rat [16]. In this assay, a micropocket is made in the stroma where 
a pellet containing the growth factors is placed inside the micropocket on the corneal surface 
of the eye. The growth factors induce a reproducible angiogenic response, and by implanting 
multiple pellets of different growth factors into parallel micropockets, the various stimuli of 
angiogenic response may be assessed. The angiogenic response in this assay is entirely due 
to direct stimulation of blood vessels instead to indirect induction of inflammation reaction. 
The assay shows minimal inflammatory cellular activity. However, the tested compounds 
are slowly released from the polymer of the micropocket, and such formulations may cause 
irritation and ultimately lead to inflammatory reactions which may alter angiogenesis quan-
tification. The micropocket itself is inaccessible to certain blood borne growth factors and 
blood progenitor cells which may influence angiogenesis. The new vasculature mainly forms 
through the sprouting from the adjacent limbal area. Being avascular in nature, the corneal 
assay is useful in visibility and accessibility of new vessel formation and topical application 
of test drugs and biomicroscopic grading of new vasculature. However, it makes the assay 
atypical because normal tissues are vascular with few exceptions [16].
5.2. Chick chorioallantoic membrane (CAM) assay
The assay was introduced by Folkman and associates, but embryologists used this method 
to evaluate embryonic tissue grafts for their developmental potential [17]. The assay is use-
ful to study tumor angiogenesis as well as pro- and anti-angiogenesis compound screening 
[18]. Fertilized hen’s egg incubated at 37°C for 3 days is prepared for grafting by removing 
enough egg albumin to reduce shell membrane adhesion. Carriers containing the tested com-
pound are placed directly onto the CAM by making a rectangular opening in the eggshell. 
Slow-release polymer pellets, air-dried disks, and gelatin sponges can be used as tested com-
pound carriers; however, Elvax 40 and Hydron which are used to form sponges and mem-
branes remain inert when applied to the CAM [19]. The quantification of angiogenesis can be 
made 3–4 days after grafting [18–20]. The in ovo CAM assay is relatively simple to perform as 
described above. However, a complementary in vitro method has also been described during 
which the chicken embryos grow in Petri dishes after 3 days of incubation. The assay is techni-
cally in vitro, but strictly speaking, it presents a whole-animal assay. After three to six days’ 
extra incubation, the CAM develops, and grafts can be assessed for subsequent development. 
In vitro CAM allows the quantification of blood vessels over a wider area than in ovo CAM 
assay. Similarly, a large number of samples can be evaluated at one time, and response occurs 
within a short period of time (i.e., 2–3 days). Furthermore, the test compound can be placed 
on the underside of the coverslips. Generally, in ovo CAM assay is performed more than in 
Recent Advances in Angiogenesis Assessment Methods and their Clinical Applications
http://dx.doi.org/10.5772/66504
301
vitro CAM. The calculated time for CAM angiogenesis response is very critical as between 
day five and twelve, the experimentally induced acceleration or suppression of embryonic 
organogenic angiogenesis can be determined. From day 12 onward, endogenous organogenic 
angiogenesis under the influence of undefined growth factor may initiate, and identification 
of newly formed vessels under the effect of tested compound becomes vague [18].
5.3. Rodent mesentery assay
The rodent mesentery assay was introduced by K. Norrby and associates in 1986 and refined 
later on [21, 22]. The peculiarity of the assay is to use the small gut mesentery of small rodents 
which is considered ideal for the physiological measurement of angiogenesis. It can be exteri-
orized from the abdominal cavity, and it’s “window” like thin membranous parts make it an 
ideal angiogenic test tissue by using intravital microscopy. Other potential advantage is that 
the intestinal mesentery of mouse, rat, guinea pig, rabbit, cat, and dog is almost identical. The 
test tissue is a 5–10 µm thin membrane which is covered by a single layer of mesothelial cells 
covered on both sides bordering onto a delicate basal membrane. The thin membrane sand-
wiches a tissue space that contains mast cells, histiocytes, fibroblasts, and some lymphocytes. 
It is the thinnest tissue found in the body of Sprague-Dawley (SD) rats. Avascular part of the 
test tissue contains predominantly 52% fibroblasts and 48% of the mesothelial cells in adult 
male SD rats. The connective tissue elements of varying size including collagen, elastin, and 
elastic fiber are also a part of mesentery test tissue [21].
A microscopic analysis clearly shows the cellular and vascular components of the mesenteric 
windows [22]. The microvessel number per mm circumference is increased in the 15-week-old 
male rat as compared to 5.5-week-old which demonstrates a slow progression of physiological 
angiogenesis to the peripheral part of the windows. The same phenomenon is noticed in female 
SD rats with an age increase; however, the increase in microvessel length, density, and vascular-
ization is not seen in untreated male SD rats at the age of 7 weeks. The distal part of the mesentery 
(i.e., standard test tissue) of these rats shows no significant angiogenesis for 2–3 weeks which is 
the usual duration of angiogenesis assay. The test compound usually in the form of an intraperi-
toneal injection (i.p.) reaches all targeted microvessel of the test tissue because the mesothelial 
cell lining is highly permeable to a wide range of the molecular weight of the test compounds. 
The test tissue is unaffected by inflammation mediated angiogenesis as it is untouched mechani-
cally, and no surgery is involved. The assay was tested for the first time for mast cell-induced 
angiogenesis and later on inflammatory cytokines, and humoral growth factors were also tested 
almost near to physiologic level doses [22].
The quantitative assessment of angiogenesis is performed by immunohistochemically 
using a specific primary monoclonal antibody against the rat endothelium. The assay 
allows clear cut identification of even the smallest newly formed vessels in the test tissue. 
Thus, the quantitative vessel parameters (as discussed on page 4) can be measured easily 
which are very vital to determine molecular activity, the effect of low molecular weight 
heparinized preparations, and dose-response curves. Computer imaging and microscopic 
morphometry may be used to further validate the immunohistochemistry findings in a 
blinded fashion [22].
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5.4. The sponge implant assays
The assay was introduced by Andrade and associates by which tested compound is directly 
injected into a sponge which is implanted subcutaneously in the rat [23]. The assay is used 
for continuous assessment of the angiogenesis as sterile polyester sponge implants become 
vascularized, and the measurement of blood flow in sponge by using Xe133 clearance tech-
nique produces reproducible and objective angiogenesis. The exudate fluid for biochemical 
analysis may be extracted after local injection of angiogenic stimulator or inhibitors. The assay 
is useful to study tumor angiogenesis as the sponge implant may replicate the hypoxic tumor 
microenvironment although the composition of sponge implant may vary [9]. The potential 
disadvantage of the assay is a nonspecific inflammatory response to sponge implant which 
may infiltrate the sponge substance as the subcutaneous implant becomes encapsulate due 
to granulation tissue. A variable composition of sponge sometimes makes inter-experimental 
comparison difficult, and use of Xe133 becomes complicated [23].
5.5. Disk angiogenesis system (DAS)
The assay was introduced to study wound healing and solid tumor angiogenesis as well as 
the angiogenic response of soluble substances in mice [24]. A synthetic foam disk composed 
of polyvinyl alcohol foam and covered on both flat sides by filters is inserted into mice abdo-
men or thorax which is well tolerated. The disk is easy to assemble, and the tested compound 
or tumor cells suspension is placed at the center of the disk. The slow release of the tested 
drug or tumor cell suspension is managed by the use of agarose or ethylene-vinyl acetate 
copolymer. The disk is removed within a period of 7–21 days, during which microvascular 
growth occurs centripetally into the disc. Paraffin-prepared sections of the disk are used to 
microscopically view the vascular growth as well as fibroblasts and connective tissue compo-
nents. The quantitative vessel parameters can be determined by point counting on histological 
sections, intravascular volume, and so on. The disadvantage of the assay is inflammation-
mediated angiogenesis as the disk is always surrounded by fibroblasts whenever vascular 
growth occurs. Similarly, the kinetic observation of newly formed vessels is difficult because 
one disk provides information for only one point in time [9].
5.6. The Matrigel plug assay
The Matrigel plug assay was introduced by Passaniti and coworkers in 1992 [25]. The Matrigel 
was extracted from Engelberth-Holm-Swarm (EHS) tumor, which is rich in ECM proteins. 
It is a solubilized basement membrane preparation which liquefies at 4°C but reconstitutes 
into a gel at 37°C when injected subcutaneously into mice where it is slowly surrounded by 
granulation tissue. The gel induces highly vascularized response under the influence of angio-
genic growth factors in particular bFGF [25]. The assay is noninvasive and easy to administer 
but time-consuming to handle.
The Matrigel composition is not fully defined. However, the major components include epi-
dermal, transforming, platelet, nerve, and insulin-like growth factors (e.g., PDGF, TGF, and 
bFGF) laminin, collagen, heparin sulfate proteoglycans, and entactin [26]. For this reason, care 
should be taken while using Matrigel assay for the cellular activity studies. It was observed 
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that when Matrigel with reduced growth factors is implanted, few cells invade the plug or 
gel. However, with known angiogenic growth factors (e.g., bFGF), mixed with Matrigel and 
injected subcutaneously, endothelial cells migrate into the gel and constitute vessel-like struc-
tures. A fine network of endothelial cell tubes enlarged by micro- and macro-vessel endothe-
lial cells slowly progress to capillary networks in vivo [26].
For the quantitative assessment of angiogenesis, Matrigel and surrounded granulation 
tissue are removed after 1–3 weeks, and immunohistochemistry and histological sections 
are measured [27]. However, determining the profiles of capillary-like vessels is difficult. 
Similarly, the hemoglobin (Hb) test does not differentiate the blood flow in newly formed 
blood vessels and large parent vessels. Fluorochrome-labeled high molecular weight dex-
tran and quantitative vascular specific indicators are alternative methods to assess neovas-
cularization [27].
The assay is suitable for tissue regeneration experiment model where neovascularization is 
coupled with organogenesis, fibrosis, and monocytes/macrophages play a pivotal structural 
role. A possible drawback of the assay is that Matrigel plug contains only capillary network 
rather than no tissue without any pro- and anti-angiogenic factors to influence angiogenic 
reactions [28].
A variation of the Matrigel plug assay is the combination of Matrigel and sponge techniques. 
Five-hundred microliters of Matrigel is injected subcutaneously into mice and solidify for 
20–30 min [27]. After that, the mice are anesthetized, skin overlying Matrigel is shaved, and a 
small nick is made. A similar nick is made to Matrigel plug, and a sterile polyvinyl sponge with 
the test compound is introduced into the center of the Matrigel plug with the help of tweezers. 
The same procedure may use for angiogenic growth factors or test tissue to be implanted in 
the Matrigel plug. By this modification, neovascularization is directional, and assay sensitiv-
ity is increased to measure direct angiogenesis as compared to standard Matrigel plug assay. 
However, the sponge/Matrigel combined assay is time-consuming, and the total number of 
assayed animals become limited [27].
5.7. Whole-animal angiogenesis model
Zebrafish was introduced in 1999 as a whole small angiogenesis model for the screening 
of pro-angiogenic compounds which directly influence the newly formed vessels [29]. The 
choice of the whole animal as a tested tissue was based on the remarkable similarity of zebraf-
ish organs to those of a human at the physiological, anatomical, and molecular levels [30]. 
Moreover, the short generation time (approx. 3 months) and easy to house in small space 
and relatively large numbers also facilitate to evaluate many tested animals in one assay [31]. 
The external development of zebrafish embryos and optical transparency during embryonic 
stage assists continuous microscopic evaluations of different developmental processes from 
gastrulation to organogenesis [30]. Furthermore, external mode of fertilization also permits 
easy access to experiment design and assessment. Small tested compounds dissolve to water 
diffuse directly to fish embryo and induce distinct and dose-dependent angiogenic effects. 
Both pro- and anti-angiogenic compounds exhibit similar effects in zebrafish as exerted in 
mammals [31].
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6. Animal models of angiogenesis
In biomedical research, mouse models are of utmost importance for a wide variety of medi-
cal tests including gene expression, gene knockout, and medical genetic analysis [32]. For 
this purpose, SCID, transgenic, and genetically engineered mouse models are of particular 
interests which allow sophisticated investigations for genetically induced pathological states 
and molecular pathogenesis of certain genetic disorders. Furthermore, such mouse models 
are useful to study genes essential for angiogenesis and vascular biology [32]. In parallel to 
that mice with conditional, global knockouts, over-expressing angiogenic factors are also con-
siderable in this prospect [33]. As remarkable similarity exists between human and murine 
vasculatures, such tools are valuable to search possible molecular interactions among distinct 
angiogenic factors in the onset and progression of various human diseases [32, 33]. In the 
following section, we shed light on some practically used mouse models in the context of 
pathological angiogenesis which directly plays a part in human diseases.
6.1. Mouse model of angiogenesis in adipose tissue
Genetically engineered mouse model for adipose tissue angiogenesis is highly reproducible 
and produces robust results because the mice are inbred and share a highly similar genetic 
background. This approach is irrelevant to humans because high caloric intake and little physi-
cal exercise are the predisposing factors for developing obesity instead a little genetics involved. 
Thus, mice fed on high-fat diet present an ideal animal model to study non-genetically related 
obesity [34].
6.1.1. Ob/ob mice
The mouse carrying the obese mutation (ob) was first described in 1950, and later on, it was 
shown that the mutation located in the gene coding for a hormone leptin, which regulates 
appetite and food intake [35]. The hormone binds to leptin receptor (Ob-R) in the hypothala-
mus and subsequent cell signaling regulates food uptake, energy expenditure as well as fat 
and glucose metabolism. Ob/ob mice are deficient in leptin exhibit uncontrolled and continu-
ous food intake which results in a gain of body weight. Consequently, mutated mice weight 
is three times higher, and body fat content elevates up to fivefold as compared to wild-type 
species. The mutated mice also show decreased physical activity and energy expenditure, 
infertility, and immune deficiencies. The mutation is recessive, so the heterozygotes do not 
display such phenotype [35]. Ob/ob mice can be used as an outstanding model to explore the 
role of angiogenesis in adipose tissue expansion, and with specific angiogenic inhibitors, obe-
sity may be prevented in such mice [36]. As the leptin kinetics in mice to regulate food intake 
and obesity are homologous to human, such angiogenic model can be used to search novel 
therapeutic targets to treat obesity and metabolic disorders [37].
6.1.2. Db/db mice
The mouse strain C57BL/KsJ was first described with an autosomal recessive mutation dia-
betes (db) in 1966 [38]. Homozygous mice with such mutation are deficient for the leptin 
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receptor and exhibit a phenotype that resembles human diabetes mellitus. The mice with 
such mutations are also characterized as an obese phenotype. Furthermore, such mice exhibit 
infertility and hyperglycemia while heterozygotes are typically lived as wild type. Db/db 
mice can be used to study molecular mechanisms involved in obesity-related diabetes and 
insulin insensitivity, and the role of angiogenesis and neovascularization can be elucidated 
in this regard [38].
6.2. Hindlimb ischemic model of angiogenesis
Most of the angiogenic models described above are very useful to study pathological angio-
genesis and search for novel anti-angiogenic treatment in the form of angiogenic inhibitors. 
However, certain pathological states (e.g., myocardial infarction, stroke, and wound heal-
ing/regeneration) in human body require accelerated blood vessel growth to reinstate the 
proper function of such vital organs [39]. In myocardial infarction, an occluded coronary 
artery obstructs blood flow to a part of the cardiac muscle tissue which leads to severe tissue 
hypoxia (ischemia). The cardiac muscle requires a regular supply of oxygen and glucose lev-
els for normal function. To overcome tissue hypoxia, the growth of highly functional arteries 
is eagerly awaited in such situations. Hind limb ischemia in rat or mice presents an excellent 
model to study and manipulate newly formed vessels in particular arteries in response to tis-
sue hypoxia [39].
In this assay, the arteries supply blood to one back limb of the mice is ligated to stop the 
blood circulation in the entire limb [40]. The occlusion of arteries leads to tissue ischemia and 
the initiation of arteriogenesis from collateral arteries. Pro-angiogenic factors and even anti-
angiogenic compounds under investigation can be administered to the limb musculature 
to modulate the arteriogenic response. Doppler angiography is used to evaluate the blood 
circulation in the hind limb, and the procedure can be repeated in the same animal to know 
that how the blood flow improves over time. To study newly formed microvessels, the tissue 
can be excised and stained, and morphology of the blood vessels is elucidated [40].
The assay is the first in class to present therapeutic angiogenesis and widely used in funda-
mental discoveries to demonstrate that how to generate highly functional and stable arteries 
therapeutically [39]. On the other side, the potential disadvantage of the assay is very compli-
cated hind limb surgery and requires highly skilled professionals and experienced surgeons. 
Similarly, the proportion of blood flow in a hind limb may vary after surgery, and it may 
affect the degrees of tissue hypoxia which ultimately influence on the therapeutic activity of 
pro- and anti-angiogenic compounds under investigation [39].
6.3. Wound healing assays
The wound healing assay allows to study and evaluate both angiogenesis and vascular matu-
ration/remodeling in injured or damaged tissues [41]. The assay is usually performed on the 
skin of mice because other accessible tissues (e.g., tail and ears) do not regenerate well. Two 
circular holes (approx. 5mm in diameter) are punched through the dorsal skin of anesthetized 
wild-type C57B16 mice. One hole would serve as control while drugs under investigation can 
be administered on the other. No bandages or sponge is required as no major blood vessels 
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exist in this region of the skin and wound formation allows very little bleeding in the sur-
rounding area. Wound sealing starts within two weeks, and complete wound healing occurs 
within a month [41].
Photography and measuring of wound area with calipers provide information about wound 
size, scar formation, and re-epithelization of the wound [41]. The drugs under investigation 
(either pro- or anti-angiogenic compounds) in this model may be administered either sys-
temically by oral administration, injection, or topically. The drug effects can be determined by 
excision of the skin tissue, fixed, and stained with specific dyes. The tested compounds may 
influence regenerative angiogenesis, vessel morphology, and function. The assay is easy to 
setup, and surgery is very simple. The wound size remains uniform and homogenous for all 
animals used in one experiment [41].
The potential disadvantage of the assay is that angiogenesis is inflammation-dependent 
involving blood clotting phenomenon and other complex biological processes and occurs 
only in the skin [41]. Similarly, skin tissue regeneration is entirely different as compared to 
other highly vascular tissues such as the heart and nervous system and does not provide an 
adequate understanding of the role of angiogenesis in tissue regeneration. Furthermore, tis-
sue regeneration is mainly due to reconstitute new tissue rather than repairing or replacing, 
which is hard to replace in ischemic insults which produce large patches of dead tissue [41].
6.4. Genetically engineered animal model for angiogenesis
Gene expression analysis and gene function studies are contributing widely to almost every 
research in life sciences, biomedical research, biotechnology, molecular pathology, and 
human health [42]. In vivo applied and functional genomic studies are particularly consid-
ered by overexpressing a candidate gene or suppressing the gene expression for the purpose 
of gene knockout [43]. Such approaches are achieved and applicable by genome manipulation 
of wild-type animals [43]. Similarly, the generation of transgenic animals by injecting desired 
DNA constructs to fertilized eggs also presents some standard technology in gene expres-
sion studies [44]. Transgenic animal models and DNA constructs (e.g., gene expression plas-
mids and vectors) with desired gene expression are widely used to study gene function and 
molecular pathogenesis of diseases, and it create models to demonstrate the complex, intri-
cate interplay between gene overexpression or suppression for the molecular epidemiology 
of human diseases [44]. In the following section, we briefly overview such novel approaches 
to be involved in the context of vascular angiogenesis.
The control of target gene expression in vascular cells of transgenic animals by cell or tis-
sue expression plasmid with specific promoters is very helpful to study developmental and 
pathological gene function in the vasculature [42]. It was found that the promoters derived 
from the sequences of VEGFR-1, ICAM-2, vWF, or endoglin efficiently work in mouse endo-
thelial cells both in vivo and in vitro with specific intensity and specificity [42]. Similarly, lacZ 
selective transgene expression was seen in ECs cells under the control of promoters derived 
from Tie 2 (angiopoietin receptor), ICAM-2, or VE-Cadherin [42]. However, the expression 
of a transgene in smooth muscle cells (SMCs) is difficult to achieve because most SMC mark-
ers are expressed differentially, and SMC growth and cell differentiation are an exclusive 
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process [42]. In contrast, transgenic mice may obtain using selective promoters expressing 
smooth muscle myosin heavy chain (SM-MHC), smooth muscle α-actin, and SM22α [42]. 
Such models provide valuable information about the function of a specific gene in a particu-
lar tissue, and controlling the expression of such genes may use as a therapeutic approach to 
certain disease and also for angiogenesis and cancer [42]. However, the transgene expression 
depends on promoter’s characteristics to be used while constructing cell or tissue expression 
plasmids with the gene of interests including; promoters is constitutively active, capable to 
express and replicate gene of interest or to express in embryonic or in the adulthood stage 
[45]. Failure to do so may limit studies in molecular pathogenesis, leads to nonviable trans-
genic animals or compensatory responses. More powerful tools are being developed based 
on conditional transgene expression systems [45].
The inhibition of endogenous gene expression is also a potential method to suppress the gene 
function involved in the molecular pathogenesis of many genetic disorders and infectious dis-
eases [46]. Many studies show that sequence-specific mRNA degradation by double-strand 
RNA strongly inhibits the function of that gene involved in pathogenesis or propagation of a 
particular disease [47]. The technique is known as RNA interference (RNAi) and may be used 
in certain genetic disorders, in cancer, HIV, and other harder to treat infections. Recent pub-
lish data indicate that mammalian expression vectors expressing short hairpin RNA (shRNA) 
under the control of specific vascular promoters inhibit gene expression through an RNAi 
effect [47].
7. Angiogenesis and cancer
The phenomenon of angiogenesis is fundamental in tumor growth, progression, and metas-
tasis [48]. Angiogenesis itself is the result of a highly orchestrated series of molecular and 
cellular events including a plethora of genes, signal cascades, and transcription factors which 
are highly organized and work in a systematic way to generate microvessels in normal physi-
ological angiogenesis [49]. However, the tumor angiogenesis is disorganized, irregular, and 
not systematic at the level of molecular and cellular events and ultimately propagates many 
tumors into cancers [48]. The cancer cells contain the ability to stimulate angiogenesis by 
producing a lot of angiogenic factors including cell growth factors, cytokines, and numerous 
other molecules [48, 49].
Many pro- and anti-angiogenic molecules involved in the induction of angiogenesis and neo-
vascularization, their receptor ligands, and intracellular signaling pathways have been identi-
fied within last 30 years [50]. Much work has been done to develop anti-angiogenic treatment 
strategies for cancer patients [51]. However, numerous preclinical trials show no promise 
regarding high efficacy and tolerability with classical anti-angiogenic drugs as monotherapy 
[51]. It spurred the researchers and investigators to design and develop novel anti-angiogenic 
compounds to be used in combination with classical cytotoxic agents and radiotherapy [52]. 
FDA-approved angiogenesis inhibitors in combination with chemotherapy have proven their 
clinical worth regarding improved patient survival time and patient tolerability in certain 
cancers [52].
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In the coming section, we briefly overview molecular mechanisms of major cell signaling 
pathways involved in the induction of angiogenesis, and at the end, some brief glimpse about 
the clinical impacts of newly developed angiogenic inhibitors will be described. The cellu-
lar events in the regeneration and propagation of tumor angiogenesis are already explained 
briefly at page 5 and depicted in Figure 1.
7.1. VEGF intracellular signaling
Vascular endothelial-derived growth factor (VEGF) is one of the most important and potent 
angiogenic molecules which play an integral role in tumor angiogenesis [50]. It presents the 
first in a class of cytokines which induce vascular leakage and therefore also known as vascu-
lar permeability factor. Until now, six members (VEGF-A to VEGF-F) of this unique family of 
cytokines have been discovered [53]. VEGF-A is mainly involved in angiogenesis and vascu-
logenesis whereas VEGF-B is a survival factor for ECs, SMCs, and pericytes [54]. VEGF-C and 
VEGF-D are essential for lymphangiogenesis, and PGF also acts as a survival factor for ECs 
and modulates VEGF cell signaling [55].
Vascular endothelial growth factors activate ECs by binding to a family of class III trans-
membrane receptor tyrosine kinases (RTKs) expressing at high levels in endothelial cell lin-
eage [53]. VEGF-R1 and VEGF-R2 are located on ECs and activate during angiogenesis while 
VEGF-R3 induces intracellular signaling in lymphatic cells. VEGF-R1 acts as a decoy recep-
tor as it is RTK defective and acts as a negative regulator of angiogenesis (Figure 2) [54]. 
The angiogenic multiple cell signaling pathways are initiated as VEGF-A binds to VEGF-R2, 
and the receptor dimerizes and intracellular receptor domains are phosphorylated in ECs 
and induce overexpression of growth factors, cell proliferation, mitogenesis, chemotaxis, and 
prosurvival signaling (Figure 2) [55]. VEGF-C binds to VEGFR-3 and initiates mitogenesis in 
lymphatic cells and stimulates hyperplasia in parent lymphatic vessels [53–55]. The produc-
tion of VEGF is regulated by several growth factors produced by the tumor cells including, 
endothelial growth factor (EGF), transforming growth factor (TGF-α & β), fibroblast growth 
factor (FGF), and platelet-derived growth factor (PDGF) [54]. Some hormones (e.g., estrogen, 
thyroid-stimulating hormone (TSH)) and interleukins (e.g., IL-1 & 6) also stimulate VEGF-
induced intracellular events in other types of cells [56].
7.2. Notch signaling pathways
The Notch receptors are located on stromal cells and expressed as a heterodimeric complex of 
two domains, that is, the Notch extracellular domain (NECD) and Notch intracellular domain 
(NICD) which are associated with each other via noncovalent interactions (Figure 3a) [57]. The 
Notch cell signaling may mimic direct tumor angiogenesis however actively involved to trigger 
dormant tumors [1]. Notch ligand Delta-like 4 (DLL4) induces cell signaling pathways to improve 
vascular functions by endocytosis and nonenzymatic dissociation of Notch heterodimer in host 
stromal cells (Figure 3a) [1]. DLL4 inhibition may promote cell proliferation response in ECs 
which ultimately increase angiogenic sprouting and vessel branching [58]. Despite increased 
endothelial cell vascularity, the tumor cells perfuse poorly, which reduces cell oxygen concen-
trations (i.e., increased hypoxia), and consequently, tumor growth is inhibited [59].
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In contrast, DLL4 expressed in ECs stimulates Notch 3 receptors located on adjacent cells (e.g., 
colorectal cancer or T-cell acute lymphoblastic leukemia cells) to activate tumor progression 
from dormant to active phase [60]. Such findings consider Notch pathways a potential thera-
peutic target for the design and development of novel anti-angiogenic compounds, although 
the Notch cell signaling shows a mixed behavior of tumor progression and inhibition in clini-
cal assays [58, 59].
7.3. Transforming growth factor-β (TGF-β)
Transforming growth factor is a ubiquitously expressed paracrine polypeptide of approxi-
mately 25 kDa molecular weight [61]. TGF 1 to TGF 3 are three highly homologous isoforms of 
the polypeptide and discovered in humans and mammals [62]. TGF-β is initially synthesized 
as a zymogen, and after secretion, an associated peptide is proteolytically sliced to release 
active form of the growth factor [63].
Active TGF-β binds to constitutively active serine/threonine kinase TGFBR2 receptors to acti-
vate TGFBR1 in a heterodimer complex which controls transcription via activation of canonical 
signal pathways mediated by a family of SMAD proteins (SMAD1-5) (Figure 3b) [64]. The 
Figure 2. VEGF-induced intracellular signaling in tumor angiogenesis and angiogenic inhibitors with targeted active sites: 
The binding of vascular endothelial growth factors (VEGF) to respective transmembrane receptors stimulates a plethora 
of intracellular signaling pathways which regulate nuclear transcription factors for altered gene expressions of normal 
cell responses including loss of tumor suppression, activation of hypoxia inducible factor (HIF-α), increased receptor 
tyrosine kinase activity, increased tumor cell growth, and repression of oncogene mutations. Angiogenic inhibitors to 
their targeted active sites are also shown with numerical circles in the figure. Only anti-angiogenic compounds approved 
by the US Food and Drug Administration (FDA) for the treatment of numerous solid tumors and carcinomas are 
depicted where circle 1 represents growth factor inhibitors (bevacizumab, aflibercept); circle 2, growth factor receptor 
inhibitors (sunitinib, sorafenib); circle 3, RAS inhibitors (tipifarnib, lonafarnib); circle 4, RAF inhibitors (sorafenib); circle 
5, HIF-1α inhibitors (geldanamycin, chetomin, echinomycin, 2ME2); circle 6, PI3K inhibitors (wortmannin, LY294002); 
circle 7, AKT inhibitors (FARA-A); and circle 8, mTOR inhibitors (rapamycin and analogues). JNK = JUN N-terminal 
kinase; MAPK = mitogen-activated protein serine/threonine kinase, MAPKK = MAPK kinase, PDK1 = phosphoinositide-
dependent protein kinase-1; PLC = phospholipase C; PtdInP2 = phosphatidylinositol 4,5-bisphosphate, Ins (1,4,5) = 
inositol 1,4,5-triphosphates.
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activation of SMAD 1 and 5 proteins in transformed cells inhibits apoptosis and mediates cell 
proliferation and migration via the activation of other cell signaling pathways [65]. However, 
in normal cells, the stimulation of SMAD 2, 3, and 4 exhibits cell cycle arrests and apoptosis 
[66]. Similarly, the SMAD 2, 3, and 4 proteins increase the expression of PAI-1which is essential 
for vessel maturation in angiogenesis (Figure 3b) [66].
8. Clinical impact of angiogenic inhibitors
The discovery and development of angiogenic inhibitors have raised the hopes to treat a lot 
of tumors and carcinomas and ultimately to reduce the morbidity and mortality related to 
tumors and cancers [67]. Five classes of anti-angiogenic compounds have established and 
are still under investigation on the basis of potential antitumor drug targeted sites including 
proteases inhibitors (MMP synthesis inhibitors), ECs proliferation and migration inhibitors, 
vascular endothelial growth factor inhibitors, cell matrix protein inhibitors, and angiogenic 
inhibitors with unique mechanisms (Figure 2) [68, 69].
Although the anti-angiogenic compounds approved by the FDA show therapeutic efficacy 
in some categories of cancer as monotherapy, however, sufficient published data recently 
reveal this fact that angiogenic inhibitors are best therapeutic choices for tumors when used in 
Figure 3. A schematic diagram of Notch and TGF-β induced cell signaling pathways in tumor angiogenesis: (a) Notch 
cell signaling pathways: The ligand DLL4 dissociates Notch heterodimers by nonenzymatic degradation and cell 
endocytosis. Notch extracellular domain exposes Notch to ADAM metalloproteases and γ-secretase in sending cells 
(tip cells) for proteolytic cleavage and the release of Notch intracellular domain which translocates to the nucleus of 
receiving cells (stalk cells) for the transcriptional activation of Notch target genes (shown in the nucleus of the stalk cells). 
The DLL4 ligand and Notch inhibitors are also depicted in the red rectangular boxes. (b) Transforming growth factor 
(TGF-β) induced intracellular signaling pathway: In normal cells, the binding of TGF-β to transmembrane TGFBR2 
receptors activates TGFBR1 receptors which upregulate the expression of a series of SMAD proteins (SMAD 2, 3, and 
4) and cause cell cycle arrest and apoptosis. However, TGF-β stimulates other molecular pathways in transformed cells 
to inhibit cell apoptosis and accelerates cell migration and metastasis. In contrast, a second type 1 receptor (ALK1) is 
expressed in ECs which stimulates cell proliferation and migration via activating SMADs 1 and 5 genes.
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combination with traditional chemotherapies [70, 71]. However, one would not expect in the 
first instance that angiogenic inhibitors might reduce the intratumoral delivery of cytotoxic 
agents (traditional chemotherapy) by decreasing perfused blood vessels with impaired blood 
flow and decrease drug transport in treated tumor cells [48, 72]. It would also increase tissue 
hypoxia and inhibit tumor cell proliferation although proliferating cells are an easy target for 
chemotherapy [48, 72].
To overcome such hurdles and to enhance synergistic therapeutic potential of chemo 
and anti-angiogenic drugs when used in combination, Kerbel proposed three mechanis-
tic approaches in this scenario to be adopted; first, normalization of tumor microvessels 
by anti-angiogenic compounds [73, 74]; second, maximum tolerated dose chemotherapy 
during the break periods of successive courses [72, 75], and third, use of known chemo-
therapeutic agents having anti-angiogenic effects [72]. The additional advantages of che-
motherapy while improving their anti-angiogenic effects may be grabbed by adopting 
“metronomic chemotherapy” which states that “the administration of chemotherapeutic 
agents at relatively low, minimally toxic doses on a frequent schedule of administration at 
regular close intervals, with no prolonged drug-free breaks [76, 77].” By such approaches, 
endothelial cells are directly killed, and progenitor ECs are suppressed in circulation. 
Furthermore, minimal use of toxic doses lowers the frequency of adverse events in treated 
patients [72, 76, 77]. Such treatment strategies may be adopted for a prolonged period of 
time with angiogenic inhibitors in the treatment of advanced solid tumors with little side 
effects as validated by phase II clinical trials; however, phase III clinical studies are exten-
sively demanded in this direction [70, 71].
9. Conclusions
In vivo, in vitro, and in ova assays for angiogenesis assessment are the reliable approaches in 
basic research and to some extent in real-world clinical practices. However, in vivo systems 
are difficult to perform and time consumable, and the process of quantification is much com-
plicated than in vitro assays. Conversely, these are relatively better due to complex nature of 
the vascular response to the test compound. In vitro angiogenesis assays may perform in a 
short period and provide the accurate and reliable outcome of angiogenic processes. Mouse 
models based angiogenesis assays have also standardized to an improved understanding of 
tumor angiogenesis and lymphangiogenesis. Similarly, such models are also used to assess 
vasculogenesis and arteriogenesis in ischemic heart diseases, blindness, psoriasis, and arthri-
tis. Angiogenesis assessment always plays a focal role to determine the pathogenesis and 
progression of certain challenging diseases in human populations in particular human can-
cer. An ample understanding of angiogenesis research in tumor progression, by knowing the 
molecular mechanisms and cellular pathways, also opens the ways to design and develop 
effective anti-angiogenic inhibitors. The manipulation of the human genome in a precise and 
predictable manner due to recently developed molecular techniques has opened new gates 
for the generation of more reliable models for angiogenesis studies and the testing of new 
therapeutic strategies.
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